Ranbaxy Mohali Plant's U.S. Acceptance May Have Hung By A Hair
This article was originally published in PharmAsia News
The U.S. FDA's ban on drugs imported from the Mohali, India, production plant of Ranbaxy Laboratories appears to have been based in part on detection of a possible arm hair embedded in a single tablet.
You may also be interested in...
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.
The UK's Advertising Standards Authority will closely monitor the marketing communications of dietary supplements e-tailer Health Solutions after it failed to provide a substantive response to health claims regulation breaches.